Follow the Telix Pharmaceuticals Limited stock price and the full management transaction log of the company, a publicly traded company based in Australia. Shares trade on AU AU, under the authority of ASX. Operating in the Health Care sector, Telix Pharmaceuticals Limited has published 9 public disclosures. Market capitalisation: €5.9bn. The latest transaction was filed on 24 June 2026 (Initial Substantial Holding). Among the most active insiders: Unknown. All data is free.
Analysts rate Telix Pharmaceuticals Limited Strong Buy (bullish), based on 12 analysts. Average price target: A$23.44.
Informational score on this market. Our backtest validates the signal only on 8 EU venues; elsewhere (notably US markets) insider buys historically invert or do not hold. Not a recommendation.
Transparent value + quality ranking, distinct from the insider signal.
Fundamental view, insider signal, bull and bear case, synthesis.
AI-generated analysis. Opinion, not investment advice. Not backtested. Built from public filings and financials. No price target, no buy or sell recommendation.
9 of 9 declarations
Telix Pharmaceuticals Limited is a biopharmaceutical company focused on developing targeted therapies for cancer. It specializes in radiopharmaceuticals and precision medicine.